Although revenue is not increasing fast, Bio-Rad has made the adjustments to bring more to the bottom line.

Source: https://investorplace.com/2023/09/3-beaten-down-biotech-stocks-bound-for-a-bounce-back/

Amundi raised its holdings in shares of Bio-Rad Laboratories by 45.0% during the fourth quarter.

Source: https://www.dailypolitical.com/2023/08/04/bio-rad-laboratories-nysebio-releases-quarterly-earnings-results-beats-expectations-by-0-45-eps.html

Ardevora Asset Management LLP grew its position in Bio-Rad Laboratories by 9.5% during the fourth quarter.

Source: https://www.etfdailynews.com/2023/05/08/bleakley-financial-group-llc-buys-shares-of-897-bio-rad-laboratories-inc-nysebio/

Atlas Capital Advisors LLC purchased a new position in Bio-Rad Laboratories in the second quarter valued at about $50,000.

Source: https://www.etfdailynews.com/2023/02/28/healthcare-of-ontario-pension-plan-trust-fund-sells-1169-shares-of-bio-rad-laboratories-inc-nysebio/

Bio-Rad Laboratories, Inc. has a 1 year low of $344.63 and a 1 year high of $572.70.

Source: https://www.etfdailynews.com/2023/07/15/asset-management-one-co-ltd-has-4-61-million-stake-in-bio-rad-laboratories-inc-nysebio/

Finally, Credit Suisse Group decreased their price target on shares of Bio-Rad Laboratories from $580.00 to $550.00 and set an outperform rating for the company in a research report on Friday, August 4th.

Source: https://www.etfdailynews.com/2023/08/10/bio-rad-laboratories-nysebio-pt-lowered-to-525-00-at-wells-fargo-company/

Finally, Putnam Investments LLC grew its position in Bio-Rad Laboratories by 107.7% in the 3rd quarter.

Source: https://www.americanbankingnews.com/2023/04/08/bio-rad-laboratories-inc-nysebio-shares-purchased-by-comerica-bank-2.html

Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Bio-Rad Laboratories has a consensus rating of “Buy” and an average price target of $664.

Source: https://www.americanbankingnews.com/2023/04/29/bio-rad-laboratories-inc-nysebio-shares-acquired-by-brinker-capital-investments-llc.html

FORA Capital LLC increased its holdings in shares of Bio-Rad Laboratories by 34.2% in the fourth quarter.

Source: https://www.etfdailynews.com/2023/05/25/dimensional-fund-advisors-lp-acquires-2920-shares-of-bio-rad-laboratories-inc-nysebio/

Guggenheim Capital LLC grew its position in shares of Bio-Rad Laboratories by 18.6% in the 3rd quarter.

Source: https://www.americanbankingnews.com/2023/05/07/dakota-wealth-management-purchases-217-shares-of-bio-rad-laboratories-inc-nysebio.html

MML Investors Services LLC increased its stake in Bio-Rad Laboratories by 13.5% in the 3rd quarter.

Source: https://www.etfdailynews.com/2023/04/10/bio-rad-laboratories-inc-nysebio-given-average-recommendation-of-buy-by-analysts/

Principal Financial Group Inc. lifted its position in shares of Bio-Rad Laboratories, Inc. () by 7.0% in the fourth quarter, reports.

Source: https://www.etfdailynews.com/2023/05/26/bio-rad-laboratories-inc-nysebio-shares-acquired-by-principal-financial-group-inc/

Royal Bank of Canada lifted their price target on shares of Bio-Rad Laboratories from $571.00 to $579.00 and gave the stock an “outperform” rating in a research report on Friday, February 17th.

Source: https://www.etfdailynews.com/2023/05/07/pacer-advisors-inc-sells-1042-shares-of-bio-rad-laboratories-inc-nysebio/

Truist Financial Corp lifted its position in Bio-Rad Laboratories by 25.7% during the 4th quarter.

Source: https://www.etfdailynews.com/2023/03/10/bio-rad-laboratories-inc-nysebio-evp-sells-849306-78-in-stock/